<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616222</url>
  </required_header>
  <id_info>
    <org_study_id>CELSIOR-TGV_2020</org_study_id>
    <nct_id>NCT04616222</nct_id>
  </id_info>
  <brief_title>A Retrospective Comparison of the Efficacy and Safety of Celsior® in Pediatric Cardiac Surgery for Transposition of the Great Vessels</brief_title>
  <acronym>CELSIOR-TGV</acronym>
  <official_title>A Retrospective Comparison of the Efficacy and Safety of Celsior® in Pediatric Cardiac Surgery for Transposition of the Great Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Celsior® is an organ preservation solution used for the harvesting and the preservation of&#xD;
      solid organs. Its use as a crystalloid cardioplegia solution has been established recently.&#xD;
      Its main advantage is the long duration of myocardial protection. Compared to the other&#xD;
      cardioplegia solutions, it allows a reduced amount of solution administered during the&#xD;
      surgery and fewer interruptions during the intervention for the administration of&#xD;
      supplemental doses of cardioplegia for long and complex operations.&#xD;
&#xD;
      The objective of this register is to compare the safety and the efficacy of Celsior® to the&#xD;
      old cardioplegia solution Saint-Thomas used as cardioplegia solution in surgery of the&#xD;
      transposition of great vessels, the arterial switch operation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death at 30 days after surgery</measure>
    <time_frame>30 days</time_frame>
    <description>Death at 30 days after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative troponin levels</measure>
    <time_frame>48 hours</time_frame>
    <description>Troponin in ng/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac rhythm assessment</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of abnormal rhythm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of pre- and post-operative creatinine levels</measure>
    <time_frame>24 hours</time_frame>
    <description>Creatinine in µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>In days</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Transposition of Great Vessels</condition>
  <arm_group>
    <arm_group_label>CELSIOR® group</arm_group_label>
    <description>Patient who received Celsior® during their transposition of the great vessels surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saint-Thomas group</arm_group_label>
    <description>Patient who received Saint-Thomas during their transposition of the great vessels surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CELSIOR® group</intervention_name>
    <description>Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.</description>
    <arm_group_label>CELSIOR® group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saint-Thomas group</intervention_name>
    <description>Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.</description>
    <arm_group_label>Saint-Thomas group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Paediatric patients with an arterial switch operation for transposition of the great&#xD;
        vessels&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient of neonatal age at the time of the intervention&#xD;
&#xD;
          -  Patients with a transposition of the great vessels with intact septum and with the&#xD;
             arterial switch operation performed as a corrective procedure&#xD;
&#xD;
          -  CELSIOR® used as cardioplegia solution between 2012 and 2019&#xD;
&#xD;
          -  Saint-Thomas used as cardioplegia solution (control group) between 2005 and 2011&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major cardiovascular malformations needing correction during the surgery for the&#xD;
             transposition of great vessels including : interventricular communication, coarctation&#xD;
             of the aorta, interruption of the aortic arch&#xD;
&#xD;
          -  Significant anomalies of coronary arteries origin or paths including : intramural&#xD;
             course, single coronary ostium&#xD;
&#xD;
          -  Opposition to participate in this retrospective research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julia MITCHELL, MD</last_name>
    <phone>472357476</phone>
    <phone_ext>+33</phone_ext>
    <email>julia.mitchell@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naoual EL JONHY</last_name>
    <phone>4 72 35 69 12</phone>
    <phone_ext>+33</phone_ext>
    <email>naoual.el-jonhy@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>: Hôpital Louis Pradel - Service de Chirurgie Cardiaque C</name>
      <address>
        <city>Bron</city>
        <zip>69477</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristian BULESCU</last_name>
      <phone>4 72 11 66 24</phone>
      <phone_ext>+33</phone_ext>
      <email>nicolae-cristian.bulescu@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transposition of Great Vessels</mesh_term>
    <mesh_term>Situs Inversus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

